Limits...
Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region.

Goh KL, Choi MG, Hsu PI, Chun HJ, Mahachai V, Kachintorn U, Leelakusolvong S, Kim N, Rani AA, Wong BC, Wu J, Chiu CT, Shetty V, Bocobo JC, Chan MM, Lin JT - J Neurogastroenterol Motil (2016)

Bottom Line: Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration.Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms.Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

ABSTRACT
Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as increased healthcare use. Proton pump inhibitors (PPIs) are currently the most effective treatment for gastroesophageal reflux disease. However, there are limitations associated with these drugs in terms of partial and non-response. Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration. Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms. Dexlansoprazole has also been shown to achieve good plasma concentration regardless of administration with food, providing flexible dosing. Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed. This review discusses the role of the new generation PPI, dexlansoprazole, in the treatment of gastroesophageal reflux disease in Asia.

No MeSH data available.


Related in: MedlinePlus

Mean plasma concentration-time profiles for dexlansopra-zole and lansoprazole in healthy participants (day 5). Adapted from Vakily et al39 with permission.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4930293&req=5

f2-jnm-22-355: Mean plasma concentration-time profiles for dexlansopra-zole and lansoprazole in healthy participants (day 5). Adapted from Vakily et al39 with permission.

Mentions: Dexlansoprazole is a novel formulation that employs a dual delayed release technology designed to prolong the concentration–time profile and provide an extended duration of acid suppression.38,39 The dual delayed release technology uses 2 types of enteric-coated granules with different pH-dependent dissolution profiles to provide an initial drug release in the proximal small intestine, at a pH of approximately 5.5, followed several hours later by another drug release at more distal regions of the small intestine, at a pH of ≥ 6.75. Dexlansoprazole therefore produces a dual-peaked pharmacokinetic profile, as opposed to the single peak seen with conventional PPIs (Fig. 2).39 Dexlansoprazole increases the mean intragastric pH and the duration that intragastric pH is > 4 over a 24-hour period.40 The optimal dose range is 30–90 mg,19 and the two doses currently approved for clinical use are 30 mg and 60 mg.


Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region.

Goh KL, Choi MG, Hsu PI, Chun HJ, Mahachai V, Kachintorn U, Leelakusolvong S, Kim N, Rani AA, Wong BC, Wu J, Chiu CT, Shetty V, Bocobo JC, Chan MM, Lin JT - J Neurogastroenterol Motil (2016)

Mean plasma concentration-time profiles for dexlansopra-zole and lansoprazole in healthy participants (day 5). Adapted from Vakily et al39 with permission.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4930293&req=5

f2-jnm-22-355: Mean plasma concentration-time profiles for dexlansopra-zole and lansoprazole in healthy participants (day 5). Adapted from Vakily et al39 with permission.
Mentions: Dexlansoprazole is a novel formulation that employs a dual delayed release technology designed to prolong the concentration–time profile and provide an extended duration of acid suppression.38,39 The dual delayed release technology uses 2 types of enteric-coated granules with different pH-dependent dissolution profiles to provide an initial drug release in the proximal small intestine, at a pH of approximately 5.5, followed several hours later by another drug release at more distal regions of the small intestine, at a pH of ≥ 6.75. Dexlansoprazole therefore produces a dual-peaked pharmacokinetic profile, as opposed to the single peak seen with conventional PPIs (Fig. 2).39 Dexlansoprazole increases the mean intragastric pH and the duration that intragastric pH is > 4 over a 24-hour period.40 The optimal dose range is 30–90 mg,19 and the two doses currently approved for clinical use are 30 mg and 60 mg.

Bottom Line: Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration.Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms.Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

ABSTRACT
Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as increased healthcare use. Proton pump inhibitors (PPIs) are currently the most effective treatment for gastroesophageal reflux disease. However, there are limitations associated with these drugs in terms of partial and non-response. Dexlansoprazole is the first PPI with a dual delayed release formulation designed to provide 2 separate releases of medication to extend the duration of effective plasma drug concentration. Dexlansoprazole has been shown to be effective for healing of erosive esophagitis, and to improve subjective well-being by controlling 24-hour symptoms. Dexlansoprazole has also been shown to achieve good plasma concentration regardless of administration with food, providing flexible dosing. Studies in healthy volunteers showed no clinically important effects on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition, with no dose adjustment of clopidogrel necessary when coprescribed. This review discusses the role of the new generation PPI, dexlansoprazole, in the treatment of gastroesophageal reflux disease in Asia.

No MeSH data available.


Related in: MedlinePlus